Experimental phage therapy in the beginning of the 21st century;La phagothérapie expérimentale à l'aube du xxie siècle

Medecine et Maladies Infectieuses

Volumn 38, Issue 8, 2008, Pages 421-425

  Debarbieux, L ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antibiotic resistance; Phage therapy

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; ENTEROBACTER INFECTION; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMAN; NONHUMAN; PSEUDOMONAS AERUGINOSA; PUBLICATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

BACTERIOPHAGES; COLIPHAGES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 52149096256     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2008.06.014     Document Type: Article

References (24)

1. Faruque S.M., Naser I.B., Islam M.J., et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc Nat Acad Sci USA 102 (2005) 1702-1707
2. Biswas B., Adhya S., Washart P., et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70 (2002) 204-210
3. Borysowski J., Weber-Dabrowska B., and Gorski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med Maywood, NJ 231 (2006) 366-377
4. Carlton R.M., Noordman W.H., Biswas B., de Meester E.D., and Loessner M.J. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol 43 (2005) 301-312
5. Entenza J.M., Loeffler J.M., Grandgirard D., Fischetti V.A., and Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49 (2005) 4789-4792
6. Kutter E.S.A. Bacteriophages, biology and applications (2005), CRC Press Inc, Boca Raton, FL, USA
7. Merril C.R., Scholl D., and Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2 (2003) 489-497
8. Nakai T., and Park S.C. Bacteriophage therapy of infectious diseases in aquaculture. Res Microbiol 153 (2002) 13-18
9. Summers W.C. Bacteriophage therapy. Ann Rev Microbiol 55 (2001) 437-451
10. Sheng H., Knecht H.J., Kudva I.T., and Hovde C.J. Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol 72 (2006) 5359-5366
11. Tanji Y., Shimada T., Fukudomi H., Miyanaga K., Nakai Y., and Unno H. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 100 (2005) 280-287
12. Xie H., Zhuang X., Kong J., Ma G., and Zhang H. Bacteriophage Esc-A is an efficient therapy for Escherichia coli 3-1 caused diarrhea in chickens. J Gen Appl Microbiol 51 (2005) 159-163
13. O'Flynn G., Ross R.P., Fitzgerald G.F., and Coffey A. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl Environ Microbiol 70 (2004) 3417-3424
14. Rees C.E., and Dodd C.E. Phage for rapid detection and control of bacterial pathogens in food. Adv Appl Microbiol 59 (2006) 159-186
15. Capparelli R., Parlato M., Borriello G., Salvatore P., and Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51 (2007) 2765-2773
16. Matsuzaki S., Yasuda M., Nishikawa H., et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187 (2003) 613-624
17. Wills Q.F., Kerrigan C., and Soothill J.S. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49 (2005) 1220-1221
18. Fischetti V.A. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 13 (2005) 491-496
19. O'Flaherty S., Coffey A., Meaney W., Fitzgerald G.F., and Ross R.P. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 187 (2005) 7161-7164
20. O'Flaherty S., Ross R.P., Meaney W., Fitzgerald G.F., Elbreki M.F., and Coffey A. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol 71 (2005) 1836-1842
21. McVay C.S., Velasquez M., and Fralick J.A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51 (2007) 1934-1938
22. Marza J.A., Soothill J.S., Boydell P., and Collyns T.A. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32 (2006) 644-646
23. Abul-Hassan H.S., El-Tahan A., Massoud B., and Gomaa R. Bacteriophage therapy of Pseudomonas burn wound sepsis. Ann Mediterr Burns Club 3 (1990) 262
24. Verbeken G., De Vos D., Vaneechoutte M., Merabishvili M., Zizi M., and Pirnay J.P. European regulatory conundrum of phage therapy. Future Microbiol 2 (2007) 485-491